title: [The hypolipidemic and liver protective effect of (Z)-N-(2-hydroxyethyl) docos-13-enamide on hyperlipidemic golden hamsters].
abstract: This study is to observe preventive effect of (Z)-N-(2-hydroxyethyl) docos-13-enamide on hyperlipidemia and fatty liver of golden hamsters. Hyperlipidemic golden hamsters fed with high-fat diet was administered orally with (Z)-N-(2-hydroxyethyl) docos-13-enamide (10, 20 and 40 mg x kg(-1)) for 5 weeks. Levels of serum and hepatic lipid content, liver histology, hepatic MDA and SOD levels, serum ALT and AST levels were evaluated in golden hamsters. (Z)-N-(2-Hydroxyethyl) docos-13-enamide has a hypolipidemic effect, and could reduce hepatic lipid content, serum ALT and AST levels, hepatic MDA level, increase hepatic SOD activity. (Z)-N-(2-Hydroxyethyl) docos-13-enamide plays an important role in reducing serum lipid, restraining hepatic fatty deposition and protecting liver to get rid of peroxidation injury of hyperlipidemic golden hamsters. The exact lipid-lowering mechanism of (Z)-N-(2-hydroxyethyl) docos-13-enamide needs further investigation.
authors.affiliation: College of Medicine, Xiamen University, Xiamen 361005, China.
authors.forename: Yan-Hui
authors.initials: YH
authors.lastname: Shen
authors.forename: Xin
authors.initials: X
authors.lastname: Jin
authors.forename: Yun
authors.initials: Y
authors.lastname: Zhao
authors.forename: Gulmira
authors.initials: G
authors.lastname: Altunbak
authors.forename: Li-Min
authors.initials: LM
authors.lastname: Lin
authors.forename: Ping
authors.initials: P
authors.lastname: Shu
authors.forename: Xiao
authors.initials: X
authors.lastname: Wei
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D002784:Cholesterol / Q000097:blood / Q000378:metabolism; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D006224:Cricetinae; D004883:Erucic Acids / Q000737:chemistry / Q000494:pharmacology*; D005234:Fatty Liver / Q000097:blood / Q000378:metabolism / Q000473:pathology; D006949:Hyperlipidemias / Q000097:blood / Q000378:metabolism / Q000473:pathology; D000960:Hypolipidemic Agents / Q000737:chemistry / Q000494:pharmacology*; D008099:Liver / Q000378:metabolism / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000378:metabolism; D008647:Mesocricetus; D011897:Random Allocation; D013482:Superoxide Dismutase / Q000378:metabolism; D014280:Triglycerides / Q000097:blood / Q000378:metabolism
chemical_list: C583814:(Z)-N-(2-hydroxyethyl) docos-13-enamide; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004883:Erucic Acids; D000960:Hypolipidemic Agents; D014280:Triglycerides; D008315:Malondialdehyde; D002784:Cholesterol; D013482:Superoxide Dismutase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase